ArticleJournal of rhinology : official journal of the Korean Rhinologic Society2025
Optimizing Human Nasal Turbinate Stem Cell Dosage for the Effective Treatment of Empty Nose Syndrome.
Article in Journal of rhinology : official journal of the Korean Rhinologic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesEmpty nose syndrome (ENS) is a chronic and debilitating condition characterized by atrophic nasal mucosa and impaired mucosal function, resulting in persistent nasal discomfort and breathing difficulties. Despite various surgical and medical interventions, an effective treatment remains elusive. This study investigated the therapeutic potential of a human nasal turbinate stem cell (hNTSC)-based therapeutic agent for ENS.
methodsENS was induced in a rabbit model via electrocautery, and varying concentrations of hNTSC-based spheroids combined with collagen hydrogel were administered (n=3 per group). Histological and mRNA expression analyses were performed one month posttreatment to assess epithelial thickness and FOXJ1 expression levels.
resultsHistological analysis revealed that hNTSC treatment significantly increased epithelial thickness, with the most pronounced effect observed in the medium-dose group (1×107 cells/mL, 50 μL). mRNA analysis showed a dose-dependent increase in FOXJ1 expression, with the highest levels observed in the high-dose group. However, this did not correlate with superior histological recovery, suggesting that epithelial remodeling is optimal at specific cell concentrations.
conclusionThese findings demonstrate that hNTSC-based therapy effectively promotes epithelial regeneration in ENS, with an optimal therapeutic dose identified at 1×107 cells/mL. This study highlights the potential clinical application of stem cell therapy for ENS and underscores the need for precise dose optimization to maximize therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.